Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway

Sun,Lina; Chen,Shuchun; Gao,Haina; Ren,Luping; Song,Guangyao

doi:10.3892/ijmm.2017.3048

Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway

Authors:
- Lina Sun
- Shuchun Chen
- Haina Gao
- Luping Ren
- Guangyao Song
View Affiliations

Affiliations: Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei 06600, P.R. China, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Graduate Student Institute, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
Published online on: July 3, 2017 https://doi.org/10.3892/ijmm.2017.3048
Pages: 637-646
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endothelial progenitor cells (EPCs) are an independent factor predicting cardiovascular events. Visfatin plays an important role in the pathogenesis of various metabolic disorders. In this study, we examined the effects of visfatin on the apoptosis of EPCs and the mechanisms underlying these effects. Cultured EPCs pre-treated with various concentrations of visfatin, FK866 (visfatin inhibitor) and BAY11-7085 [referred to as BAY11; nuclear factor-κB (NF-κB) inhibitor] were used to investigate the association between visfatin and EPC apoptosis. Following treatment with visfatin for 48 h, the EPCs exhibited a dose-dependent increase in apoptosis and an upregulated expression of Bax, caspase-3 and NF-κB at both the mRNA and protein level, and a decreased protein expression of Bcl-2. Compared with the untreated control group, the increase in EPC apoptosis, as well as in Bax and caspase-3 expression was significant following treatment with 150 ng/ml visfatin, which also induced a dose-dependent and significant increase in the protein expression of interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1). All the visfatin-induced effects were suppressed by pre-treatment with FK866. Pre-incubation of the EPCs with BAY11 for 1 h followed by treatment with visfatin (150 ng/ml) for 48 h also abolished visfatin-induced apoptosis; it also abolished the promoting effects of visfatin on the expression of caspase-3, Bax, ICAM-1 and IL-6, and its suppressive effects on the protein expression of Bcl-2. On the whole, our data indicate that visfatin induces EPC apoptosis by increasing the expression of pro-inflammatory mediators partly through the regulation of NF-κB.

View Figures

View References

1	Samal B, Sun Y, Stearns G, Xie C, Suggs S and McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 14:1431–1437. 1994. View Article : Google Scholar : PubMed/NCBI
2	Garten A, Petzold S, Schuster S, Körner A, Kratzsch J and Kiess W: Nampt and its potential role in inflammation and type 2 diabetes. Handb Exp Pharmacol. 203:147–164. 2011. View Article : Google Scholar
3	Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I, Karkos C, Karayannacos PE, Gerasimidis T and Liapis CD: Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 118:75–80. 2010. View Article : Google Scholar
4	Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C, Petramala L, Minisola S, D'Erasmo E and Letizia C: Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest. 34:e12–e15. 2011. View Article : Google Scholar
5	Unlütürk U, Harmanci A, Yildiz BO and Bayraktar M: Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf). 72:469–474. 2010. View Article : Google Scholar
6	de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O and de la Fuente B: Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev. 29:576–581. 2013.PubMed/NCBI
7	Chen S, Sun L, Gao H, Ren L, Liu N and Song G: Visfatin and oxidative stress influence endothelial progenitor cells in obese populations. Endocr Res. 40:83–87. 2015. View Article : Google Scholar
8	Boini KM, Zhang C, Xia M, Han WQ, Brimson C, Poklis JL and Li PL: Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta. 1801:1294–1304. 2010. View Article : Google Scholar : PubMed/NCBI
9	Xiao K, Zou WH, Yang Z, Rehman Zia ur, Ansari AR, Yuan HR, Zhou Y, Cui L, Peng KM and Song H: The role of visfatin on the regulation of inflammation and apoptosis in the spleen of LPS-treated rats. Cell Tissue Res. 359:605–618. 2015. View Article : Google Scholar
10	van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D and Pickering JG: Pre-B-cell colony-enhancing factor regulates NAD⁺-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 97:25–34. 2005. View Article : Google Scholar : PubMed/NCBI
11	Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
12	Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A, Bermejo E, Carraro R, Sánchez-Ferrer CF and Peiró C: Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One. 6:e272992011. View Article : Google Scholar : PubMed/NCBI
13	Urbich C and Dimmeler S: Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res. 95:343–353. 2004. View Article : Google Scholar : PubMed/NCBI
14	Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S and Zeiher AM: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation. 111:2981–2987. 2005. View Article : Google Scholar : PubMed/NCBI
15	Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M and Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 353:999–1007. 2005. View Article : Google Scholar : PubMed/NCBI
16	Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ and Kaplan MJ: Interferon-alpha promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood. 110:2907–2915. 2007. View Article : Google Scholar : PubMed/NCBI
17	Fujii H, Li SH, Szmitko PE, Fedak PW and Verma S: C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 26:2476–2482. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tie G, Yan J, Yang Y, Park BD, Messina JA, Raffai RL, Nowicki PT and Messina LM: Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase/Akt pathway. J Vasc Res. 47:519–530. 2010. View Article : Google Scholar : PubMed/NCBI
19	Sun Y, Chen S, Song G, Ren L, Wei L, Liu N, Zhang D and Lv X: Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. Int J Mol Med. 30:622–628. 2012.PubMed/NCBI
20	Bakogiannis C, Tousoulis D, Androulakis E, Briasoulis A, Papageorgiou N, Vogiatzi G, Kampoli AM, Charakida M, Siasos G, Latsios G, et al: Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes. Curr Med Chem. 19:2597–2604. 2012. View Article : Google Scholar : PubMed/NCBI
21	Peng J, Liu B, Ma QL and Luo XJ: Dysfunctional endothelial progenitor cells in cardiovascular diseases: Role of NADPH oxidase. J Cardiovasc Pharmacol. 65:80–87. 2015. View Article : Google Scholar
22	Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R and Zhivotovsky B: Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene. 21:65–77. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
24	Salvesen GS and Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell. 91:443–446. 1997. View Article : Google Scholar : PubMed/NCBI
25	Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59(Suppl 7): 1693s–1700s. 1999.PubMed/NCBI
26	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar
27	Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, et al: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res. 42:268–273. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Ingram DA, Murphy MP, Saadatzadeh MR, Mead LE, Prater DN and Rehman J: Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 296:H1675–H1682. 2009. View Article : Google Scholar : PubMed/NCBI
29	Adamis AP and Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 30:65–84. 2008. View Article : Google Scholar : PubMed/NCBI
30	Satofuka S, Ichihara A, Nagai N, Yamashiro K, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, et al: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci. 47:2686–2692. 2006. View Article : Google Scholar : PubMed/NCBI
31	Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P and Muthukkaruppan V: Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina. 28:817–824. 2008. View Article : Google Scholar : PubMed/NCBI
32	Tang JN, Shen DL, Liu CL, Wang XF, Zhang L, Xuan XX, Cui LL and Zhang JY: Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris. Am J Med Sci. 349:130–136. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, et al: Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 180:165–176. 2012. View Article : Google Scholar
34	Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N and Kohsaka H: Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 60:2505–2512. 2009. View Article : Google Scholar : PubMed/NCBI
35	Kitagawa K, Matsumoto M, Sasaki T, Hashimoto H, Kuwabara K, Ohtsuki T and Hori M: Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis. 160:305–310. 2002. View Article : Google Scholar : PubMed/NCBI
36	Bielinski SJ, Pankow JS, Li N, Hsu FC, Adar SD, Jenny NS, Bowden DW, Wasserman BA and Arnett D: ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 201:339–344. 2008. View Article : Google Scholar : PubMed/NCBI
37	Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6:a0162952014. View Article : Google Scholar : PubMed/NCBI
38	Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, et al: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 1783:886–895. 2008. View Article : Google Scholar : PubMed/NCBI
39	Wan R, Liu Y, Li L, Zhu C, Jin L and Li S: Urocortin increased endothelial ICAM1 by cPLA2-dependent NF-kappaB and PKA pathways in HUVECs. J Mol Endocrinol. 52:43–53. 2013. View Article : Google Scholar
40	Matsuda A, Yang WL, Jacob A, Aziz M, Matsuo S, Matsutani T, Uchida E and Wang P: FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice via NF-κB pathway. Ann Surg. 259:1007–1017. 2014. View Article : Google Scholar
41	Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM and Randeva HS: A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 31:51–57. 2010. View Article : Google Scholar
42	Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, et al: Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. Cell. 130:1095–1107. 2007. View Article : Google Scholar : PubMed/NCBI
43	Hasmann M and Schemainda I: FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63:7436–7442. 2003.PubMed/NCBI
44	Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B and Löser R: WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 62:1057–1062. 2002.PubMed/NCBI
45	Crabtree HG: Observations on the carbohydrate metabolism of tumours. Biochem J. 23:536–545. 1929. View Article : Google Scholar : PubMed/NCBI
46	Kroemer G and Pouyssegur J: Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
47	Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR and Randeva HS: Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: Parallel increase in plasma visfatin. J Clin Endocrinol Metab. 91:5022–5028. 2006. View Article : Google Scholar : PubMed/NCBI
48	Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Więcek A and Chudek J: Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy. J Am Soc Hypertens. 9:1–8. 2015. View Article : Google Scholar
49	Rongvaux A, Galli M, Denanglaire S, Van Gool F, Drèze PL, Szpirer C, Bureau F, Andris F and Leo O: Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 4685–4695. 2008. View Article : Google Scholar : PubMed/NCBI
50	Borradaile NM and Pickering JG: Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell. 8:100–112. 2009. View Article : Google Scholar : PubMed/NCBI
51	Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and I3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008. View Article : Google Scholar